此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项随机、活性对照、评估者设盲试验,旨在确定单剂CERVAVAC®四价HPV疫苗与Gardasil®四价疫苗在赞比亚9至14岁女孩和男孩及15至20岁女孩/女性中免疫原性的非劣效性 (CervALONE)

2026年10月2日 更新者:Ravivarman Lakshmanasamy、International Agency for Research on Cancer

一项随机、活性对照、评估者设盲试验,旨在评估单剂CERVAVAC®四价HPV疫苗与Gardasil®四价疫苗在赞比亚9至14岁女孩和男孩以及15至20岁女孩/女性中免疫原性的非劣效性

The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls/women in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.

研究概览

研究类型

介入性

注册 (估计的)

1266

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Lusaka、赞比亚
        • Chipata and Matero First Level Hospitals

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

9年 至 20年 (孩子、成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Girl/woman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.
  2. Participant willing to sign a written informed consent (for participants 18 years of age and above).
  3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).
  4. Participant or parent (s) willing to comply with all study requirements.
  5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.

Exclusion Criteria:

  1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.
  2. Participant has a known history of prior vaccination with any HPV vaccine.
  3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)
  4. Participant currently enrolled in any other clinical studies of investigational products.
  5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.
  6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.
  7. Participant has a history of any allergic diseases or severe allergic reaction to any agent/vaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).
  8. Participant has had an acute illness (moderate or severe) and/or fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.
  9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.
  10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.
  11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of >0.5 mg/kg/day), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.
  12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.
  13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.
  14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.
  15. Participant has history of any cancer, organ transplant or any other immune system disease.
  16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Girls/women and boys vaccinated with single dose CERVAVAC-4 vaccine

CERVAVAC-4 single dose vaccine will be administered - off label in one arm

CERVAVAC-4 single dose vaccine

其他名称:
  • CERVAVAC单剂量

Gardasil-4 single dose

其他名称:
  • 加卫苗-4疫苗
有源比较器:Girls/women and boys vaccinated with single dose Gardasil-4 vaccine

Gardasil-4 single dose vaccine will be administered in one arm

CERVAVAC-4 single dose vaccine

其他名称:
  • CERVAVAC单剂量

Gardasil-4 single dose

其他名称:
  • 加卫苗-4疫苗

研究衡量的是什么?

主要结果指标

结果测量
大体时间
通过Meso-scale Discovery (MSD®)平台采用M9ELISA方法检测第24个月采集的血样,评估抗HPV 16和18型IgG抗体的几何平均滴度(GMT)
大体时间:24个月
24个月

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年1月15日

研究注册日期

首次提交

2025年11月20日

首先提交符合 QC 标准的

2025年11月20日

首次发布 (实际的)

2025年12月1日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅